Penserra Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43K | Buy |
754
+583
| +341% | +$33.5K | ﹤0.01% | 808 |
|
|
2026
Q1 | $10K | Hold |
171
| – | – | ﹤0.01% | 864 |
|
|
2025
Q4 | $9K | Buy |
171
+6
| +4% | +$289 | ﹤0.01% | 856 |
|
|
2025
Q3 | $7K | Hold |
165
| – | – | ﹤0.01% | 856 |
|
|
2025
Q2 | $7K | Hold |
165
| – | – | ﹤0.01% | 842 |
|
|
2025
Q1 | $10K | Sell |
165
-5,137
| -97% | -$299K | ﹤0.01% | 892 |
|
|
2024
Q4 | $299K | Sell |
5,302
-1,521
| -22% | -$85K | 0.01% | 661 |
|
|
2024
Q3 | $352K | Buy |
6,823
+6,658
| +4,035% | +$312K | 0.01% | 591 |
|
|
2024
Q2 | $7K | Sell |
165
-3,758
| -96% | -$168K | ﹤0.01% | 1035 |
|
|
2024
Q1 | $211K | Sell |
3,923
-6,868
| -64% | -$350K | ﹤0.01% | 722 |
|
|
2023
Q4 | $552K | Sell |
10,791
-1,639
| -13% | -$86K | 0.01% | 522 |
|
|
2023
Q3 | $720K | Sell |
12,430
-2,048
| -14% | -$125K | 0.01% | 422 |
|
|
2023
Q2 | $925K | Buy |
14,478
+13,223
| +1,054% | +$887K | 0.02% | 393 |
|
|
2023
Q1 | $86K | Sell |
1,255
-44,757
| -97% | -$3.16M | ﹤0.01% | 790 |
|
|
2022
Q4 | $3.31M | Buy |
46,012
+43,921
| +2,100% | +$3.31M | 0.07% | 229 |
|
|
2022
Q3 | $148K | Sell |
2,091
-42,830
| -95% | -$3.11M | ﹤0.01% | 689 |
|
|
2022
Q2 | $3.46M | Buy |
44,921
+42,452
| +1,719% | +$3.23M | 0.09% | 217 |
|
|
2022
Q1 | $179K | Buy |
2,469
+1,881
| +320% | +$126K | ﹤0.01% | 743 |
|
|
2021
Q4 | $36K | Buy |
588
+66
| +13% | +$3.87K | ﹤0.01% | 1104 |
|
|
2021
Q3 | $30K | Buy |
522
+117
| +29% | +$7.71K | ﹤0.01% | 1176 |
|
|
2021
Q2 | $27K | Buy |
+405
| New | +$26.4K | ﹤0.01% | 1105 |
|
|
2021
Q1 | – | Sell |
-16,265
| Closed | -$1.01M | – | 1116 |
|
|
2020
Q4 | $1.01M | Sell |
16,265
-464
| -3% | -$28.5K | 0.02% | 312 |
|
|
2020
Q3 | $1.01M | Sell |
16,729
-55,596
| -77% | -$3.35M | 0.04% | 266 |
|
|
2020
Q2 | $4.25M | Buy |
72,325
+67,355
| +1,355% | +$4.03M | 0.22% | 127 |
|
|
2020
Q1 | $303K | Buy |
4,970
+3,458
| +229% | +$211K | 0.02% | 404 |
|
|
2019
Q4 | $96K | Buy |
+1,512
| New | +$86.6K | 0.01% | 608 |
|
|
2018
Q4 | – | Sell |
-5,336
| Closed | -$331K | – | 634 |
|
|
2018
Q3 | $331K | Buy |
5,336
+754
| +16% | +$44.7K | 0.02% | 360 |
|
|
2018
Q2 | $253K | Buy |
4,582
+478
| +12% | +$25.8K | 0.02% | 294 |
|
|
2018
Q1 | $259K | Buy |
4,104
+324
| +9% | +$20.8K | 0.02% | 235 |
|
|
2017
Q4 | $231K | Buy |
3,780
+594
| +19% | +$37.2K | 0.03% | 216 |
|
|
2017
Q3 | $205K | Buy |
3,186
+378
| +13% | +$22.1K | 0.05% | 195 |
|
|
2017
Q2 | $156K | Buy |
+2,808
| New | +$153K | 0.06% | 248 |
|
|
2017
Q1 | – | Sell |
-312
| Closed | -$18K | – | 589 |
|
|
2016
Q4 | $18K | Sell |
312
-1,647
| -84% | -$90K | ﹤0.01% | 681 |
|
|
2016
Q3 | $105K | Buy |
1,959
+956
| +95% | +$61.4K | 0.01% | 267 |
|
|
2016
Q2 | $74K | Buy |
1,003
+334
| +50% | +$23.6K | 0.01% | 230 |
|
|
2016
Q1 | $41K | Buy |
669
+181
| +37% | +$11.4K | ﹤0.01% | 306 |
|
|
2015
Q4 | $33K | Buy |
+488
| New | +$32.2K | ﹤0.01% | 303 |
|
Other funds holding BMY
Penserra Capital Management's BMY Position: Q2 2026 in Review
Penserra Capital Management increased its Bristol-Myers Squibb (BMY) stake by 341% in Q2 2026, buying an estimated $33.5K and bringing the position to 754 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #808.
Penserra Capital Management first reported a position in BMY in Q4 2015 and has held it in 37 quarters since. The position peaked at $4.25M in Q2 2020. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Penserra Capital Management held 754 shares of Bristol-Myers Squibb worth $43K as of Q2 2026.
- Penserra Capital Management bought 583 Bristol-Myers Squibb shares in Q2 2026, an estimated $33.5K.
- Bristol-Myers Squibb made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #808 holding.
- Penserra Capital Management first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 37 quarters since.
- Penserra Capital Management's Bristol-Myers Squibb position peaked at $4.25M in Q2 2020.
- 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.